High-protein diet may increase risk of weight gain, death for those at risk for heart disease
the ONA take:
According to findings presented last week at the European Congress on Obesity in Prague, Czech Republic, researchers have found that a high-protein diet may increase the risk of weight gain and early death for those at risk for heart disease.
For the study, researchers analyzed data from over 7,000 men and women aged 55 and over without heart disease.
Researchers assessed their protein consumption for about 5 years using food questionnaires. Although participants did not have heart disease, they all had either type 2 diabetes or three or more risk factors for heart disease, such as hypertension, smoking, dyslipidemia, and obesity.
Results showed that when protein replaced fat, risk of death increased by 66% and when protein replaced carbohydrates, it was increased by 59%.
When protein replaced carbohydrates, participants had a 90% higher risk of gaining more than 10% of body weight.
Diets rich in animal protein have also been associated with an elevated risk of colon cancer, diabetes, and heart disease.
A high-protein diet may increase the risk of weight gain and early death for those at risk for heart disease.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|